To compare the incident risk of each of the 13 obesity-associated cancers (OACs) in patients with T2D who were prescribed GLP-1 RAs vs. insulin or metformin, a recent cohort study in the US evaluated some 1.6 million patients with T2D who had no prior diagnosis of the 13 OACs [39]. This evidence concerns the gene INS and type 2 diabetes mellitus.